asikkk/iStock via Getty Images
So far, I covered Edwards Lifesciences (NYSE:EW) twice on Seeking Alpha - and in both cases I was rather cautious about the stock as an investment. My first article was published in April 2021 - and
Edwards Lifesciences: Slowly Approaching Its Intrinsic Value
Summary
- Edwards Lifesciences is still reporting solid top-line growth in Q1/23 but the bottom line declined and fiscal 2022 also saw low growth rates.
- Aside from actual growth rates in the last few quarters, Edwards Lifesciences is a high-quality business with a wide economic moat based on patents and switching costs.
- For the years to come, analysts as well as management are expecting double-digit growth rates again.
- Even when considering double-digit growth rates, EW stock still seems to be a bit overvalued and not a good investment.
My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap companies).My academic background is in sociology and I hold a Master’s Degree in Sociology (with main emphasis on organizational and economic sociology) and a Bachelor’s Degree in Sociology and History.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.